The U.S. Department of Health and Human Services has launched a broad initiative to expand and accelerate clinical trials, according to Endpoints News.
The effort comes from the Trump administration, which Endpoints News reports is responding to a steady stream of calls from the biotech and pharmaceutical industries to modernize and expedite the way clinical trials are run. According to the outlet, the initiative is sweeping in scope and spans across HHS, the federal department that oversees agencies central to drug development and public health.
Clinical trials are the studies that test whether a new drug or treatment is safe and works before it can reach patients. They are often slow and expensive, and industry groups have long argued that the process needs to be streamlined. The new HHS effort is aimed squarely at that complaint, seeking both to expand access to trials and to shorten the time they take.
The details available so far are limited, but Endpoints News frames the move as a department-wide response rather than a single narrow rule change.
Why it matters: faster, broader clinical trials could shorten the path from lab to pharmacy for new medicines, but how the changes are implemented will determine whether speed comes at any cost to the safety checks the trial system is designed to protect.